https://www.selleckchem.com/pr....oducts/compound-3i.h
8%), digestive malignancies (120/692, 17.3%), and hematological malignancies (106/692, 15.3%). The association between TNFi and malignancy was evaluated in 11 studies (39.3%) no significant association was found in 10 studies, while an increased risk of lymphoma in patients exposed to TNFi was reported in one study. TNFi treatment is not associated with an increased risk of malignancy in IBD-patients in real-life settings. Further large studies are needed to assess prognosis of patients exposed to TNFi and risk of recurrence or new
Like
Comment
Share
